首页 正文

Efficacy and safety of the cystic fibrosis transmembrane conductance regulator inhibitor GLPG2737 for autosomal dominant polycystic kidney disease: phase 2a MANGROVE study

{{output}}
Background: There is a need for improved disease-targeting therapies for autosomal dominant polycystic kidney disease (ADPKD). This study evaluated the efficacy and safety of GLPG2737, a cystic fibrosis transmembrane conductance ... ...